TICKERNERD
Menu
WGSWGSHealthcare · Diagnostics & Research

WGS Stock Forecast: GeneDx Holdings Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$101
−3.67% on the day

The 9 Wall Street analysts covering GeneDx Holdings Corp. hold a median 12-month price target of $90 — -11.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$3.1B
Ticker Nerd rank
44 / 100
Median analyst target
$90
Analysts covering
9
Revenue$114.4M+11.4% y/y
Operating income−$15.2M
Net income−$17.7M
Free cash flow−$39.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+18.6%
1M
+32.4%
YTD
−22.3%
1Y
−22.7%
From 52W high
−39.6%
From 52W low
+193.0%
$35
$168
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WGS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GeneDx Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
78
Accruals
73
Revisions
67
Value
52
Growth
43
Volatility
42
Momentum
34
Size
30
Issuance
17

Quality (78): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WGS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WGS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Oct 25Jan 26Apr 26Jul 26WGSHigh $103Median $90Low $74

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $74Median $90High $103

The green dot is the last close — the median target sits −11.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026BTIGReiteratesBuy$90
4 Aug 2026Canaccord GenuityMaintainsBuy$75 → $90
29 June 2026GuggenheimMaintainsBuy$70 → $74
29 June 2026GuggenheimMaintainsBuy—
23 June 2026Piper SandlerMaintainsOverweight—
23 June 2026Piper SandlerMaintainsOverweight$50 → $63
5 May 2026BTIGMaintainsBuy—
5 May 2026Canaccord GenuityMaintainsBuy—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026Wells FargoMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsBuy—
30 Mar 2026GuggenheimMaintainsBuy—
24 Feb 2026BTIGMaintainsBuy—
24 Feb 2026Piper SandlerMaintainsOverweight—
9 Feb 2026Wells FargoUpgradeOverweight—
22 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025Wells FargoMaintainsEqual-Weight—
12 Dec 2025BTIGMaintainsBuy—
4 Nov 2025Wells FargoMaintainsEqual-Weight—
29 Oct 2025BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WGS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

WGS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, GeneDx Holdings Corp. returned −22.7% against +16.3% for the S&P 500, dividends included.

WGS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26WGSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WGS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+15.9%
Analysts raising
3
Analysts cutting
2
Fundamentals

GeneDx Holdings Corp. (WGS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
724.6×

Cheaper than 1% of US stocks

Price / sales
6.6×

Cheaper than 20% of US stocks

Price / book
12.3×

Cheaper than 8% of US stocks

EV / EBITDA
−93.9×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
11.4%

Higher than 56% of US stocks

Earnings growth (YoY)
11.4%

Higher than 50% of US stocks

Gross margin
68.4%

Higher than 81% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−23.4%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−40.8%

Higher than 24% of US stocks

Return on assets
−7.9%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GeneDx Holdings Corp. (WGS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GeneDx Holdings Corp. has a market value of $3.1B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 30 June 2026: $454.4M. The latest quarter grew 11.4% year on year.

  • Net income over the same four quarters: −$106.4M, a −23.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.8M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: 724.6×; forward P/E: 86.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • GeneDx Holdings Corp. employs 1,300 people — $350K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

WGS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
WGSGeneDx Holdings Corp.$3.1B
44
CDNACareDx, Inc.$2.8B
100
VCYTVeracyte, Inc.$3.2B
95
NEONeoGenomics, Inc.$2.6B
77
GRALGRAIL, Inc.$3.6B
36
FRNMFreenome, Inc.$1.9B
36
ADPTAdaptive Biotechnologies Corp.$4.6B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GeneDx Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WGS news & analysis

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

Business Wire · 9 Sept 2026positive

GeneDx and Beren Therapeutics announced the launch of NPC GenomeComplete, a new offering aimed at improving the diagnosis of Niemann-Pick Disease Type C. The announcement was made by GeneDx from its headquarters in Gaithersburg, Maryland.

Why it matters — This expansion of GeneDx's diagnostic portfolio into a specific rare disease area could broaden its testing offerings and relevance for stakeholders tracking the company's growth.

3 Promising Genomics Stocks in the Spotlight in 2026

Zacks Investment Research · 8 Sept 2026positive

Zacks Investment Research highlighted GeneDx Holdings Corp. (WGS) alongside NEO and NTLA as promising genomics stocks for 2026, noting that these companies are advancing diagnostics and precision medicine as genomics reshapes healthcare.

Why it matters — The mention positions WGS among leading genomics companies advancing diagnostics and precision medicine, giving watchers a positive industry-level signal.

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

Business Wire · 1 Sept 2026positive

Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree in the Health Equity category, as announced in a Business Wire release. The recognition highlights her leadership at the company.

Why it matters — External recognition of the company's CEO could raise GeneDx's profile and credibility within the healthcare industry.

Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside

Benzinga · 26 Aug 2026neutral

Benzinga reported a top-10 list of the most heavily short sold stocks, led by Venture Global with more than 80% of its float sold short, according to Benzinga Pro data. The report highlights a familiar batch of volatile, heavily bet-against names.

Why it matters — As a stock known for volatility and high short interest, GeneDx Holdings (WGS) may appear on such short-seller watch lists, making this coverage relevant to WGS watchers tracking bearish positioning.

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's

Business Wire · 24 Aug 2026positive

GeneDx and Seattle Children's announced a study supporting hospital-wide adoption of rapid genomic sequencing, which they say accelerates accurate diagnosis and expands access to answers for children. The announcement was made via Business Wire from GeneDx's headquarters in Gaithersburg, Maryland.

Why it matters — The study highlights GeneDx's rapid genomic sequencing as a scalable hospital-wide diagnostic tool, potentially broadening its clinical adoption and relevance for WGS shareholders.

FAQ

Frequently asked questions about WGS stock

What is the WGS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering GeneDx Holdings Corp. have a median 12-month price target of $90, with estimates ranging from $74 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WGS stock a buy right now?

Of the 9 analysts covering GeneDx Holdings Corp., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeneDx Holdings Corp. 44 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WGS?

As at 19 Sept 2026, GeneDx Holdings Corp. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).

Will WGS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -11.0% from the last close, and Ticker Nerd's factor model ranks GeneDx Holdings Corp. 44 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WGS stock forecast for 2030?

No analyst covering GeneDx Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WGS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $103 over the next 12 months.

How has WGS stock performed over the past year?

GeneDx Holdings Corp. returned -22.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics.

What is the latest news on WGS?

The most recent item we track (Business Wire, 9 Sept 2026): "GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C". GeneDx and Beren Therapeutics announced the launch of NPC GenomeComplete, a new offering aimed at improving the diagnosis of Niemann-Pick Disease Type C. The announcement was made by GeneDx from its headquarters in Gaithersburg, Maryland.

Company

About GeneDx Holdings Corp.

GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics. GeneDx provides pediatric and rare disease testing centered on whole exome and whole genome sequencing, along with data and information services that support more precise diagnosis and care decisions. The company also offers AI-enabled tools for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Its services are used by clinicians, hospitals, and healthcare organizations that rely on genomic information to guide patient evaluation and treatment. GeneDx Holdings Corp. plays a specialized role in the healthcare market by combining laboratory testing, bioinformatics, and clinical expertise to deliver actionable genetic insights for complex medical cases.

CEO Ms. Katherine A. Stueland · 1,300 employees · United States · https://www.genedx.com